- Independent
research carried out by Chinese and Australian scientists shows that the
Pressure BioSciences Pressure Cycling Technology (PCT) platform is
excellent for the processing of preserved (formalin-fixed
paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are
considered invaluable for discovering cancer biomarkers
- Such
tissues play a pivotal role in cancer research and may potentially
contribute to the development of therapies and prevention protocols
- Cancer
research is one of the more rapidly growing sectors making use of PBIO’s
technology; to prepare for further expansion in the future, the company
has appointed a new, highly experienced chief financial officer
- The
company recently announced that Daniel J. Shea has joined the team as chief
financial officer and senior vice president, in anticipation of growth
Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and
powerful Pressure Cycling Technology (PCT) platform has performed excellently
during the processing of preserved (FFPE) and fresh frozen biopsy tissue
samples for the discovery of cancer biomarkers, as indicated by two recently
published scientific articles about the technology’s performance.
Independent teams of scientists from China and Australia led
the research, and their data suggest that the Pressure BioSciences technology
could potentially be used in the clinical diagnostic process based on the
cancer biomarkers, as the company noted in a press release (http://ibn.fm/DfmC7). Chinese
researchers purchased their first two PCT platforms in 2017 and subsequently
purchased four additional systems. In Australia, the PCT platform has been in
use since 2016.
Because of the large amount of support data on preserved
tissue samples like the ones used in the Chinese and the Australian research
studies, such samples are considered invaluable for the retrospective study of
disease progression and response to therapy. The use of such samples could
speed up the discovery of new therapies and preventative strategies, but, up
until now, the successful extraction of high-quality biomolecules from FFPE
samples has been difficult to accomplish, at best.
According to Pressure BioSciences president and CEO Richard
T. Schumacher, over one billion archival tissue samples exist in pathology and
other laboratories across the world. Millions of additional samples are
processed and stored every single year. These samples contain an abundance of
information that could be key to the discovery of new cancer biomarkers,
development of new cancer diagnostics, and release of new treatments and
prevention measures, Schumacher concluded.
“We believe that our PCT platform is establishing itself as
the method of choice for the superior extraction of potential biomarkers and
their presentation for the effective proteomic analyses that will propel the
growth of this huge market,” Pressure BioSciences’ director of marketing and
sales Roxana McCloskey added.
The global cancer biomarker market is anticipated to reach
more than $157 billion by 2022. This is just one of the multiple important
applications of Pressure BioSciences’ innovative pressure-based technology
platform.
To prepare for the anticipated growth in the years to come,
Pressure BioSciences announced a strategic team addition on September 17, 2019.
According to an official company announcement, Daniel J. Shea has joined the
team as chief financial officer and senior vice president (http://ibn.fm/3rLyE).
Shea has over 30 years of experience in leading and advising
financial organizations. Since the beginning of 2017, Shea has operated a CPA
advisory firm called Woodcliff Advisors LLC, which provides counsel to boards,
CFOs and members of senior management teams.
“PBIO’s unique platform technologies, worldwide customer
base, growing revenue stream, and strong management team position the company
well to capitalize on substantial growth opportunities across the globe. I
stand ready to support the company’s commitment to high-quality financial
reporting and internal control as it navigates through these opportunities in
the coming years,” Shea said, commenting on the appointment.
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
